Biological bases for a probable impact of cannabidiol in Parkinson’s illness.



Existing pharmacotherapy of Parkinson’s illness (PD) is palliative and unable to modify the progression of neurodegeneration. Treatment options that can boost patients’ high quality of life with fewer side effects are required, but not however accessible. Cannabidiol (CBD), the significant non-psychotomimetic constituent of cannabis, has received considerable study focus in the final decade. In this context, we aimed to critically critique the literature on possible therapeutic effects of CBD in PD and talk about clinical and preclinical proof supporting the putative neuroprotective mechanisms of CBD.


We searched MEDLINE (by means of PubMed) for indexed articles published in English from inception to 2019. The following search phrases had been utilised: cannabis cannabidiol and neuroprotection endocannabinoids and basal ganglia Parkinson’s animal models Parkinson’s history Parkinson’s and cannabidiol.

Final results:

Handful of research addressed the biological bases for the purported effects of CBD on PD. Six preclinical research showed neuroprotective effects, even though 3 targeted the antidyskinetic effects of CBD. 3 human research have tested CBD in sufferers with PD: an open-label study, a case series, and a randomized controlled trial. These research reported therapeutic effects of CBD on non-motor symptoms.


Further study is required to elucidate the possible effectiveness of CBD in PD and the underlying mechanisms involved.


Latest posts